quinazolines has been researched along with dihydrotestosterone in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, C; Luttrell, LM; Price, DT | 1 |
| Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
| Earp, HS; Gregory, CW; Liu, Y; Majumder, S; McCall, W; Mohler, JL; Sartor, CI; Whang, YE | 1 |
| Angelucci, C; Iacopino, F; Lama, G; Sica, G | 1 |
4 other study(ies) available for quinazolines and dihydrotestosterone
| Article | Year |
|---|---|
Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines.
Topics: Cell Division; Dihydrotestosterone; Enzyme Inhibitors; Epidermal Growth Factor; Flavonoids; Humans; Male; Mitogen-Activated Protein Kinases; Phosphorylation; Prostatic Neoplasms; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 2000 |
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dihydrotestosterone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; Quinazolines; Tosyl Compounds; Transplantation, Heterologous | 2005 |
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Topics: Acetylation; Androgen Receptor Antagonists; Androgens; Cell Line, Tumor; Chromatin; Chromatin Immunoprecipitation; Dihydrotestosterone; ErbB Receptors; Gefitinib; Histones; Humans; Immunoglobulin Fragments; Lapatinib; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Response Elements; Transcription, Genetic | 2005 |
Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Humans; Leuprolide; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasms, Hormone-Dependent; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Tyrphostins | 2006 |